secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001193125-25-113291
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Q1 cash $636.6M; veligrotug BLA on track for H2 2025
-------------------------------------------------------------

- Cash, cash equivalents, and short-term investments $636.6M at March 31, 2025, down from $717.6M in December 2024; runway into H2 2027.
- R&D expenses $76.8M in Q1 2025 vs $40.9M in Q1 2024, driven by more clinical trials and increased headcount.
- Veligrotug BLA submission to FDA on track for H2 2025; EMA MAA expected in H1 2026.
- Phase 3 topline data for VRDN-003 (subcutaneous TED) expected H1 2026 from REVEAL-1 and REVEAL-2 trials.
- VRDN-006 phase 1 healthy volunteer data expected Q3 2025; VRDN-008 IND submission targeted for year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525113291/0001193125-25-113291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525113291/d937417d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-113291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer